GRIGRI Bio
About GRI Bio
GRI Bio (NASDAQ:GRI) is a clinical-stage biotech taking a new approach to inflammatory diseases. They target NKT cells, immune system regulators, to interrupt disease progression. Their lead program, GRI-0621, is a potential treatment for idiopathic pulmonary fibrosis, a serious lung condition. With a library of over 500 compounds, GRI Bio has the potential for a growing pipeline of treatments.
What is GRI known for?
Snapshot
Public US
Ownership
2009
Year founded
4
Employees
La Jolla, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of GRI Bio
- Developing therapies: They focus on treatments for inflammatory, fibrotic, and autoimmune diseases.
- NKT cell targeting: Their approach targets Natural Killer T (NKT) cells to regulate the immune system.
- Drug pipeline: They have a pipeline of drug candidates, with GRI-0621 being the most advanced.
- Pre-clinical and clinical trials: Their drugs are currently in pre-clinical and clinical trial phases, not yet available for commercial use.
- Compound library: They have a library of over 500 proprietary compounds which could fuel future drug development.
GRI Bio executive team
- Dr. W. Marc Hertz Ph.D.Co-Founder, CEO, President & Director
- Dr. Vipin Kumar Chaturvedi Ph.D.Co-Founder & Chief Scientific Officer
- Ms. Leanne M. KellyCFO & Corporate Secretary
- Dr. Albert Agro Ph.d.Co-Founder & Chief Medical Officer